HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
CT 1746
Also Known As:
CT-1746; CT1746; N1-(2-(3,3-dimethylbutanamidyl))-N4-hydroxy-2-(3-(4-chlorophenyl)propyl)succinamide
Networked:
4
relevant articles (
2
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
CT 1746: 4
Experts
1.
Heersche, J N M
: 1 article (10/2004)
2.
Manolson, M F
: 1 article (10/2004)
3.
Shorey, S
: 1 article (10/2004)
Related Diseases
1.
Neoplasm Metastasis (Metastasis)
03/01/1997 - "
Significant efficacy of CT1746 was observed on primary tumor growth (32% reduction in mean tumor area at day 36), total spread and metastasis (6/20 treated animals had no detectable spread and metastasis at autopsy compared to 100% incidence of secondaries in control groups).
"
03/01/1997 - "
Efficacy of CT1746 could also be seen on reducing tumor spread and metastasis to individual organ sites such as the abdominal wall, cecum and lymph nodes compared to vehicle and untreated controls.
"
01/01/1998 - "
In other studies employing long-term treatment with CT1746, an orally active gelatinase inhibitor, we have previously demonstrated a reduction in primary tumour growth rates, localized spread, and spontaneous metastasis, even when the treatment was commenced several days after tumour implantation.
"
02/15/1996 - "
The combination of CT1746 and cyclophosphamide (CTX) was significantly more effective than either single agent in delaying local tumor growth (CT1746/CTX, 30.9 +/- 1.7 days; CT1746, 2.6 +/- 0.3 days; CTX, 19.5 +/- 1.1 days; P < .001) and reducing the number and size of pulmonary metastases [CT1746/CTX, 5 +/- 2 (15% metastases > 3 mm); CT1746, 15 +/- 4 (55% > 3 mm); CTX, 11 +/- 3 (63% > 3 mm); no treatment, 24 +/- 5 (62% > 3 mm); P < .001].
"
02/15/1996 - "
Primary tumors, pulmonary metastases, and sera from tumor-bearing animals had increased gelatinase B activity that was inhibited by CT1746 levels achievable in vivo.
"
2.
Neoplasms (Cancer)
03/01/1997 - "
In this model CT1746 significantly prolonged the median survival time of the tumor-bearing animals from 51 to 78 days.
"
03/01/1997 - "
Significant efficacy of CT1746 was observed on primary tumor growth (32% reduction in mean tumor area at day 36), total spread and metastasis (6/20 treated animals had no detectable spread and metastasis at autopsy compared to 100% incidence of secondaries in control groups).
"
03/01/1997 - "
Efficacy of CT1746 could also be seen on reducing tumor spread and metastasis to individual organ sites such as the abdominal wall, cecum and lymph nodes compared to vehicle and untreated controls.
"
02/15/1996 - "
The combination of CT1746 and cyclophosphamide (CTX) was significantly more effective than either single agent in delaying local tumor growth (CT1746/CTX, 30.9 +/- 1.7 days; CT1746, 2.6 +/- 0.3 days; CTX, 19.5 +/- 1.1 days; P < .001) and reducing the number and size of pulmonary metastases [CT1746/CTX, 5 +/- 2 (15% metastases > 3 mm); CT1746, 15 +/- 4 (55% > 3 mm); CTX, 11 +/- 3 (63% > 3 mm); no treatment, 24 +/- 5 (62% > 3 mm); P < .001].
"
02/15/1996 - "
Primary tumors, pulmonary metastases, and sera from tumor-bearing animals had increased gelatinase B activity that was inhibited by CT1746 levels achievable in vivo.
"
3.
Lewis Lung Carcinoma
02/15/1996 - "
The efficacy of combination therapy including an oral gelatinase inhibitor (CT1746) and cytotoxic agent was analyzed using the murine Lewis lung carcinoma model.
"
4.
Colonic Neoplasms (Colon Cancer)
03/01/1997 - "
In this study, we describe the activity of CT1746, an orally-active synthetic MMP inhibitor that has a greater specificity for gelatinase A, gelatinase B and stromelysin than for interstitial collagenase and matrilysin, in a nude mouse model that better mimics the clinical development of human colon cancer.
"
5.
Bone Resorption
10/01/2004 - "
The differential involvement of the two classes of proteases was assessed by analyzing dose-dependent effects of the matrix metalloproteinase inhibitor, CT-1746, and of the cathepsin inhibitor, E64, on bone resorption.
"
Related Drugs and Biologics
1.
Matrix Metalloproteinase Inhibitors
2.
Cytotoxins (Cytolysins)
3.
Matrix Metalloproteinase 9 (Gelatinase B)
4.
Matrix Metalloproteinase 7 (Matrilysin)
5.
Matrix Metalloproteinase 1 (Interstitial Collagenase)
6.
Matrix Metalloproteinase 2 (Gelatinase A)
7.
Matrix Metalloproteinase 3 (Stromelysin 1)
8.
Peptide Hydrolases (Proteases)
9.
Cyclophosphamide (Cytoxan)
10.
Cathepsins
Related Therapies and Procedures
1.
Therapeutics